Introduction: Malignant mesothelioma (MM) is an aggressive cancer that primarily arises from the pleura (MPM) or peritoneum (MPeM), mostly due to asbestos exposure. This study reviewed the Dutch population-based incidence, treatment and survival since the national ban on asbestos in 1993. Materials and methods: Patients with MPM or MPeM … [Read more...]
Malignant pleural mesothelioma patients’ experience by gender: findings from a cross-sectional UK-national questionnaire
OBJECTIVES: Malignant mesothelioma is an aggressive malignancy of mesothelial surfaces, most commonly those of the pleura. The aim of this study was to understand, using a national questionnaire, the gendered care experiences of patients with malignant pleural mesothelioma (MPM). Patients were asked about their experience of the diagnostic process, … [Read more...]
Malignant pleural mesothelioma patients’ experience by gender: findings from a cross-sectional UK-national questionnaire
OBJECTIVES: Malignant mesothelioma is an aggressive malignancy of mesothelial surfaces, most commonly those of the pleura. The aim of this study was to understand, using a national questionnaire, the gendered care experiences of patients with malignant pleural mesothelioma (MPM). Patients were asked about their experience of the diagnostic process, … [Read more...]
Asbestos Exposure and Malignant Mesothelioma in Construction Workers
Notwithstanding the ban in 1992, asbestos exposure for workers in the construction sector in Italy remains a concern. The purpose of this study is to describe the characteristics of malignant mesothelioma (MM) cases recorded by the Italian registry (ReNaM) among construction workers. Incident mesothelioma cases with a definite asbestos exposure … [Read more...]
Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma
We compared less invasive surgery with conventional surgery for malignant pleural mesothelioma (MPM). We retrospectively reviewed consecutive patients with MPM who received surgery at Hyogo College of Medicine between July 2004 and April 2016. Patients underwent multimodal treatment comprising chemotherapy (neoadjuvant and/or adjuvant) and surgery … [Read more...]
Immune Checkpoint Inhibitors Extend Survival for Mesothelioma
Immune checkpoint inhibitor (ICI) therapies have ushered in an exciting new phase of clinical research and treatment for malignant pleural mesothelioma (MPM), offering more effective and less toxic treatment options for patients. The research and clinical oncology communities eagerly await the completion of several upcoming trials focused on … [Read more...]
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
INCIDENCE AND EPIDEMIOLOGY Incidence Incidence of malignant pleural mesothelioma (MPM) is generally higher in males than females and is attributed to historical differences in [ asbestos exposure ] with world-standardised incidence rates per 100,000 persons of 0.7 and 0.3 in the USA and 1.7 and 0.4 for Europe (for males and females, … [Read more...]
Imfinzi-Chemo Combo Improves Survival for Mesothelioma
Imfinzi plus platinum-pemetrexed chemotherapy induced survival improvements in patients with previously untreated, unresectable malignant pleural mesothelioma, compared with chemotherapy alone. Treatment with Imfinzi (durvalumab) plus platinum-pemetrexed chemotherapy was associated with improved survival among patients with previously untreated, … [Read more...]
Immunotherapy combination maintains OS advantage in malignant pleural mesothelioma
The combination of [ Opdivo and Yervoy ] maintained its survival advantage over chemotherapy with at least 3 years of follow-up among patients with unresectable malignant pleural mesothelioma, according to CheckMate 743 study results. Researchers observed the benefit of the first-line immunotherapy regimen despite patients having been off … [Read more...]
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
Background: There is a preclinical rationale for inhibiting angiogenesis in mesothelioma. We aimed to assess the efficacy and safety of the anti-VEGFR-2 antibody ramucirumab combined with gemcitabine in patients with pretreated malignant pleural mesothelioma [ as a second-line treatment ]. Methods: RAMES was a multicentre, randomised, … [Read more...]
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- Next Page »